Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο:
https://hdl.handle.net/10442/19189
Εξειδίκευση τύπου : | Άρθρο σε επιστημονικό περιοδικό |
Τίτλος: | Drugs for Vector-Borne Protozoal Diseases in a One Health Scenario. A European Perspective |
Δημιουργός/Συγγραφέας: | Cordeiro da Silva, Anabela [EL] Καλογεροπούλου, Θεοδώρα[EN] Calogeropoulou, Theodora Costi, Maria Paola Alunda, José María |
Ημερομηνία: | 2024-11-08 |
Γλώσσα: | Αγγλικά |
ISSN: | 2373-8227 2373-8227 |
DOI: | 10.1021/acsinfecdis.4c00339 |
Άλλο: | 39471826 |
Περίληψη: | Vector-borne protozoal diseases (VBPD) represent an enormous health and economic burden, particularly in low- and middle-income countries. Their control requires integrated approaches that consider not only therapeutic interventions for affected human and animal populations but also preventive tools. Environmental contamination can lead to therapeutic ineffectiveness. Effective intervention must consider in-depth knowledge of the environmental factors that regulate the exposure, transmission and pathogenicity of VBPD within a One Health approach. In recent decades, the incidence and prevalence of VBPD have been substantially reduced in many regions of the world, although there are still hot spots and emerging epidemiological cycles. Except for a partially protective vaccine against malaria, vaccination is not available for any other human VBPD, and therefore epidemiological control and chemotherapy are the main control tools. Current therapeutics have several drawbacks, including reduced efficacy, toxicity and high price of safer formulations. In addition, the industrial pipeline is limited, and no therapeutic breakthroughs are expected. Integrated control of VBPD requires multitarget control systems adapted to the disease and region. In this scenario, harmonized surveillance systems, accurate reporting and increased public and private investment will ensure more rational use of the few available and new drugs. |
Τίτλος πηγής δημοσίευσης: | ACS infectious diseases |
Τόμος/Κεφάλαιο: | 10 |
Τεύχος: | 11 |
Θεματική Κατηγορία: | [EL] Επιδημίες. Επιδημιολογία[EN] Epidemics. Epidemiology [EL] Θεραπευτική. Φαρμακολογία[EN] Therapeutics.Pharmacology [EL] Ιατρική-Δημόσια υγεία[EN] Medicine - public aspects [EL] Μικροβιολογία[EN] Microbiology |
Λέξεις-Κλειδιά: | EMA one health vector borne protozoal diseases leishmaniasis sleeping sickness chagas disease |
EU Grant: | COST Action |
EU Grant identifier: | CA21111 |
Κάτοχος πνευματικών δικαιωμάτων: | © 2024 The Authors. Published by American Chemical Society |
Όροι και προϋποθέσεις δικαιωμάτων: | This publication is licensed under CC-BY-NC-ND 4.0. |
Ηλεκτρονική διεύθυνση στον εκδότη (link): | https://doi.org/10.1021/acsinfecdis.4c00339 |
Εμφανίζεται στις συλλογές: | Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο
|